Duchenne Muscular Dystrophy Drugs Market Size, Share & Trends Analysis Report By Treatment (Molecular Based, Steroid Based, NSAIDs), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global Duchenne muscular dystrophy drugs market size was valued at USD 3.47 billion in 2023 and is projected to grow at a CAGR of 16.8% from 2024 to 2030. The market growth is due to the rising prevalence of Duchenne muscular dystrophy (DMD) disease, genetic research growth, and increased research and development funding. Gene editing and molecular biology technology advancements lead to precise and efficient therapies. Furthermore, financial support from governments, non-profit groups, and pharmaceutical companies is aiding in research and development in this field. Hence, these factors are responsible for the growth of the Duchenne muscular dystrophy (DMD) drugs market.

Ongoing developments in the healthcare sector and the rise in patient awareness drive the awareness and diagnosis of DMD. DMD is caused by mutations in DMD genes, resulting in severe muscle damage. According to the National Library of Medicine, one in 3600 male patients is diagnosed with DMD. However, it is cited as one of the most common hereditary neuromuscular diseases. The growing interest in researchers on drug development for DMD underscores the development of clinical solutions.

Partnerships between biotech companies and universities are promoting the advancement of cutting-edge treatments. Efforts from major pharmaceutical and healthcare institutes fast-track the approval of orphan drugs, enhance market growth, and drive improvements in the line of treatment for DMD patients. Furthermore, technological advancements in the healthcare sector have led to the easy availability of medicines. Hence, patients with high disposable incomes are increasingly opting for treating DMD disease. Government initiatives regarding disease awareness and favorable financial aid offered by government hospitals have resulted in a rise in the number of diagnoses of DMD.

Treatment Insights

The molecular based therapies segment dominated the market in 2023 with a share of 42.0% due to the rising prevalence of DMD disease and rising preference for molecular based therapies as they directly treat the genetic root cause of DMD. Molecular treatment is designed according to specific genetic mutations, offering personalized treatment to the patients. Furthermore, the growing awareness, research, and development to expand treatment alternatives have resulted in market growth.

The steroid based therapies composite segment is expected to grow at a CAGR of 16.2% during the forecast period owing to the predominance of steroid-based therapies to treat DMD. Steroids delay the progression of muscle damage, which assists in improving the patient’s mobility. Steroid based therapies have been a predominant choice of treatment for a long time. Therefore, the treatment options offer the best outcomes for patients undergoing this line of treatment.

Distribution Channel Insights

Hospital pharmacies dominated the market with a share of 41.4% in 2023 due to the rise in drug availability and therapies for treating DMD disease. Major healthcare and pharmaceutical institutes aim to control side effects and enhance the outcomes. These specialized drugs are distributed with the help of hospital pharmacies, as they have a strong distribution channel.

The online pharmacies segment is expected to grow at a CAGR of 16.7% during the forecast period. The market growth is due to a rise in online demand through online applications with home delivery options. The growing e-commerce in the medical sector has reduced delivery times and improved consumer service. Online pharmacies also offer valid certifications for authentic delivery of medicines. Furthermore, the presence of multiple options and the availability of online reviews and feedback encourage consumers to purchase the needed drugs.

Regional Insights

North America Duchenne muscular dystrophy (DMD) drugs market dominated with a market share of 45.0% in 2023 attributed to the presence of major healthcare institutes and the rise in the number of patients suffering from DMD. The government and major research institutes focus on improving the treatment of DMD in patients. Furthermore, the availability of treatment options drives the need for DMD.

U.S. Duchenne Muscular Dystrophy Drugs Market Trends

The U.S. Duchenne muscular dystrophy (DMD) drugs market held a substantial market share in 2023 in North America. The market growth is due to the rising prevalence of DMD disease and the presence of a developed healthcare sector. Rising awareness regarding the disease has led to an increase in the number of patients seeking the diagnosis of DMD disease. Furthermore, favorable insurance policies and government initiatives have increased the demand for DMD treatments.

Asia Pacific Duchenne Muscular Dystrophy Drugs Market Trends

The Asia Pacific Duchenne muscular dystrophy (DMD) drugs market was identified as a lucrative region in this industry in 2023 due to the rising awareness about DMD, as governments and NGOs implement regional public health initiatives. The growth in the healthcare sector aids the market growth, as hospitals are investing in technological advancements.

The China Duchenne muscular dystrophy (DMD) drugs market is expected to grow rapidly due to favorable government initiatives and improvements in the healthcare infrastructure. The government has implemented various health campaigns to raise awareness regarding DMD. Furthermore, the growing population has allowed major market players to expand in the country.

Europe Duchenne Muscular Dystrophy Drugs Market Trends

Europe held a significant market share in 2023 owing to the presence of major medical institutes and research centers allowing better research of DMD. Major pharmaceutical companies are also investing heavily to improve the quality of treatment. Furthermore, increased awareness regarding the diagnosis of the disease has also led to the increased demand for DMD treatment.

The UK Duchenne muscular dystrophy (DMD) drugs market is expected to grow rapidly due to the rising prevalence of DMD disease and growth in the healthcare sector. A strong network of medical institutes has also encouraged the discovery and innovation of DMD therapies. Furthermore, favorable medical policies such as the National Health Service have also led to increased accessibility of the treatment to patients.

Key Duchenne Muscular Dystrophy Drugs Company Insights

Some major companies in the Duchenne muscular dystrophy (DMD) drugs market are Aurobindo Pharma, Capricor Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., EspeRare Foundation, and others. Companies are focusing on improving the efficacy of the drugs, treatments and reducing the drug’s side effects.

• Aurobindo Pharma is a pharmaceutical company specializing in producing and distributing generic pharmaceuticals and active pharmaceutical ingredients. The company deals with cardiovascular products, antibiotics, antiretrovirals, cardiovascular products, and more.

• Capricor Therapeutics, Inc. is a biotechnology company that develops and distributes biologics and drugs to treat and prevent diseases. The company specializes in developing exosome-based and transformative cell therapeutics for treating muscular and other selective diseases.

Recent Developments

• In March 2024, Santhera Pharmaceuticals announced the new drug application (NDA) for Vamorolone in Duchenne muscular dystrophy accepted by China National Medical Products Administration (NMPA). The Duchenne muscular dystrophy has affected a large population in China. The licensing enables the development and commercializing of DMD drug.

• In March 2024, Catalyst Pharmaceuticals, Inc. announced the availability of the drug AGAMREE in the U.S. for treating DMD. The drug was launched for patients over two years of age to improve patient treatment for rare DMD disease.

Duchenne Muscular Dystrophy Drugs Market Report Scope

Global Duchenne Muscular Dystrophy Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Duchenne muscular dystrophy (DMD) drugs market report based on treatment, distribution channel, and region.

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Molecular Based Therapies

    • Mutation Suppression

    • Exon Suppression

  • Steroid Based Therapies

  • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait